DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The druggability of targets is a crucial consideration in drug target selection. Here, we adopt a stochastic semi-supervised ML framework to develop DrugnomeAI, which estimates the druggability likelihood for every protein-coding gene in the human exome. DrugnomeAI integrates gene-level properties from 15 sources resulting in 324 features. The tool generates exome-wide predictions based on labelled sets of known drug targets (median AUC: 0.97), highlighting features from protein-protein interaction networks as top predictors. DrugnomeAI provides generic as well as specialised models stratified by disease type or drug therapeutic modality. The top-ranking DrugnomeAI genes were significantly enriched for genes previously selected for clinical development programs (p value < 1 × 10−308) and for genes achieving genome-wide significance in phenome-wide association studies of 450 K UK Biobank exomes for binary (p value = 1.7 × 10−5) and quantitative traits (p value = 1.6 × 10−7). We accompany our method with a web application (http://drugnomeai.public.cgr.astrazeneca.com) to visualise the druggability predictions and the key features that define gene druggability, per disease type and modality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Szklarczyk, D., Gable, A. L., Lyon, D., Junge, A., Wyder, S., Huerta-Cepas, J., Simonovic, M., Doncheva, N. T., Morris, J. H., Bork, P., et al. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1131 · Cited by 17,749
UniProt: the universal protein knowledgebase in 2021
The UniProt Consortium, Bateman, A., Martin, M.-J., Orchard, S., Magrane, M., Agivetova, R., Ahmad, S., Alpi, E., Bowler-Barnett, E. H., Britto, R., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa1100 · Cited by 6,372
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“…concept in drug discovery that in fl uences target identi fi - cation and may impact the clinical development success concept of the “ druggable genome ” was fi rst introduced in 2002 1 , and was then de fi ned as the ability of a protein to bind a modulator and provide a desired therapeutic effect.”
BackgroundThe InterPro protein families and domains database: 20 years on
Blum, M., Chang, H.-Y., Chuguransky, S., Grego, T., Kandasaamy, S., Mitchell, A., Nuka, G., Paysan-Lafosse, T., Qureshi, M., Raj, S., et al. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa977 · Cited by 2,231 · cited 1×
“The InterPro database 45 is publicly available at https://www.ebi.ac.uk/ interpro.”
BackgroundRouillard, A. D., Gundersen, G. W., Fernandez, N. F., Wang, Z., Monteiro, C. D., McDermott, M. G., & Ma’ayan, A. (2016) · Database · doi:10.1093/database/baw100 · Cited by 1,515
Comparative Toxicogenomics Database (CTD): update 2021
Davis, A. P., Grondin, C. J., Johnson, R. J., Sciaky, D., Wiegers, J., Wiegers, T. C., & Mattingly, C. J. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkaa891 · Cited by 1,107
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · cited 1×
“In addition, protein-protein interactions are linked to biological and pathological processes and, recently, protein-protein interactions have gained increasing attention as drug targets due to their potential for selectively modulating speci fi c pathways 32,33 .”
King, E. A., Davis, J. W., & Degner, J. F. (2019) · PLOS Genetics · doi:10.1371/journal.pgen.1008489 · Cited by 649
BioWordVec, improving biomedical word embeddings with subword information and MeSH
Zhang, Y., Chen, Q., Yang, Z., Lin, H., & Lu, Z. (2019) · Scientific Data · doi:10.1038/s41597-019-0055-0 · Cited by 455
An, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363 · cited 1×
“We selected these modalities since small molecule and monoclonal antibody inhibitors are two of the main types of targeted therapies, and PROTAC technology is an emerging modality that can overcome some of the drawbacks of small molecule-based therapies 36 .”
Method
Cited by
The impact of AI on modern oncology from early detection to personalized cancer treatment
Li, J., Zhang, L., Yu, Z., Bao, Z., Li, D., & Wang, L. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01276-6 · Cited by 24
“A predictive model called DrugnomeAI was created by Raies et al. 279 to tackle theproblemoftargeteddrugsynthesis.”
An in-depth review of AI-powered advancements in cancer drug discovery
Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15
Cunningham, M., Pins, D., Dezső, Z., Torrent, M., Vasanthakumar, A., & Pandey, A. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00735-7 · Cited by 13
Metadata
- Authors
- Raies, A., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D.
- Venue
- Communications Biology
- Published
- 2022-11-24
- Volume
- 5
- Issue
- 1
- Pages
- 1291-1291
- ISSN
- 2399-3642 (ISSN-L)
- OpenAlex
- W4310057196
- Cited by
- 61
- References
- 16
- FWCI
- 5.57
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets. https://app.cochat.ai/papers/10.1038/s42003-022-04245-4
- The paper
- Raies, A., Tulodziecka, E., Stainer, J., Middleton, L., Dhindsa, R. S., Hill, P., Engkvist, O., Harper, A. R., Petrovski, S., & Vitsios, D. (2022). DrugnomeAI is an ensemble machine-learning framework for predicting druggability of candidate drug targets. Communications Biology. https://doi.org/10.1038/s42003-022-04245-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.